WATERTOWN, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the
development of RNAi-based therapeutics, today announced that it granted
stock options to Pankaj Bhargava, M.D., the Company's chief medical
officer, on April 16, 2014, including a stock option to purchase 246,406
shares of common stock of the Company outside of the Company's
stockholder approved equity incentive plan. The grant of this stock
option was approved by the compensation committee of the board of
directors on April 16, 2014 as an inducement material to Dr. Bhargava
entering into employment with the Company in reliance on NASDAQ Listing
Rule 5635(c)(4). Dr. Bhargava joined the Company as chief medical
officer on March 31, 2014. The stock option has an exercise price per
share of $16.30, the closing price per share of Company's common stock
as reported by NASDAQ on April 16, 2014 and is scheduled to vest over a
four-year period, subject to his continued service with the Company. Dr.
Bhargava's other compensation information is summarized in a Current
Report on Form 8-K previously filed by the Company with the Securities
and Exchange Commission.
This press release is a required notice under NASDAQ Listing Rule
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined.
Dicerna is using its proprietary RNA interference (RNAi) technology
platform to build a broad pipeline in these therapeutic areas and
intends to discover, develop and commercialize novel therapeutics either
on its own or in collaboration with pharmaceutical partners.
Dicerna Pharmaceuticals, Inc.
James B. Weissman, 617-621-8097
MacDougall Biomedical Communications
Senior Vice President
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media